产品展示
PD 0332991 HCl
点击次数：188发布时间：2013/4/7 10:56:21
更新日期：2022/8/19 17:45:40
所 在 地：美洲
产品型号：
优质供应
详细内容
PD 0332991 HCl
上海义森生物科技有限公司
技术数据:
分子量（MW）: 483.99 
化学式: C24H29N7O2.HCl
溶解度: DMSO 3mg/mL Water 30mg/mL Ethanol <1mg/mL 纯度: >99% 稳定性: at -20℃ 2 years CAS号: 827022-32-2, 571190-30-2 （free base）
生物活性
PD 0332991 HCl is an orally available pyridopyrimidine-derived cyclin-dependent kinase （CDK） inhibitor with potential antineoplastic activity. This compound is a highly specific inhibitor of cyclindependent kinase 4 （Cdk4） （IC50, 0.011 μmol/L） ａnd Cdk6 （IC50, 0.016 μmol/L）, having no activity against a panel of 36 additional protein kinases. [1]
Therapeutic doses of PD 0332991 HCl cause elimination of phospho-Rb ａnd the proliferative marker Ki-67 in tumor tissue ａnd downregulation of genes under the transcriptional control of E2F. [1]
This agent shows significant inhibition in a broad spectrum of human tumor xenografts in vivo. [2]
技术数据:
分子量（MW）: 483.99 化学式: C24H29N7O2.HCl
溶解度: DMSO 3mg/mL Water 30mg/mL Ethanol <1mg/mL 纯度: >99% 稳定性: at -20℃ 2 years CAS号: 827022-32-2, 571190-30-2 （free base）
生物活性
PD 0332991 HCl is an orally available pyridopyrimidine-derived cyclin-dependent kinase （CDK） inhibitor with potential antineoplastic activity. This compound is a highly specific inhibitor of cyclindependent kinase 4 （Cdk4） （IC50, 0.011 μmol/L） ａnd Cdk6 （IC50, 0.016 μmol/L）, having no activity against a panel of 36 additional protein kinases. [1]
Therapeutic doses of PD 0332991 HCl cause elimination of phospho-Rb ａnd the proliferative marker Ki-67 in tumor tissue ａnd downregulation of genes under the transcriptional control of E2F. [1]
This agent shows significant inhibition in a broad spectrum of human tumor xenografts in vivo. [2]
技术数据:
分子量（MW）: 483.99 化学式: C24H29N7O2.HCl
溶解度: DMSO 3mg/mL Water 30mg/mL Ethanol <1mg/mL 纯度: >99% 稳定性: at -20℃ 2 years CAS号: 827022-32-2, 571190-30-2 （free base）
生物活性
PD 0332991 HCl is an orally available pyridopyrimidine-derived cyclin-dependent kinase （CDK） inhibitor with potential antineoplastic activity. This compound is a highly specific inhibitor of cyclindependent kinase 4 （Cdk4） （IC50, 0.011 μmol/L） ａnd Cdk6 （IC50, 0.016 μmol/L）, having no activity against a panel of 36 additional protein kinases. [1]
Therapeutic doses of PD 0332991 HCl cause elimination of phospho-Rb ａnd the proliferative marker Ki-67 in tumor tissue ａnd downregulation of genes under the transcriptional control of E2F. [1]
This agent shows significant inhibition in a broad spectrum of human tumor xenografts in vivo. [2]
技术数据:
| 分子量（MW）: | 483.99 | |
|---|---|---|
| 化学式: | C24H29N7O2.HCl | |
| 溶解度: | DMSO 3mg/mL Water 30mg/mL Ethanol <1mg/mL | |
| 纯度: | >99% | |
| 稳定性: | at -20℃ 2 years | |
| CAS号: | 827022-32-2, 571190-30-2 （free base） |
生物活性
PD 0332991 HCl is an orally available pyridopyrimidine-derived cyclin-dependent kinase （CDK） inhibitor with potential antineoplastic activity. This compound is a highly specific inhibitor of cyclindependent kinase 4 （Cdk4） （IC50, 0.011 μmol/L） ａnd Cdk6 （IC50, 0.016 μmol/L）, having no activity against a panel of 36 additional protein kinases. [1]
Therapeutic doses of PD 0332991 HCl cause elimination of phospho-Rb ａnd the proliferative marker Ki-67 in tumor tissue ａnd downregulation of genes under the transcriptional control of E2F. [1]
This agent shows significant inhibition in a broad spectrum of human tumor xenografts in vivo. [2]
